FDA Class II Recall: CareFusion 213 LLC's BD PurPrep Antiseptic Faces Sterility Assurance Deficiencies
CareFusion 213 LLC has initiated a Class II recall for specific lots of its BD PurPrep Povidone-iodine and Isopropyl Alcohol Sterile Solution due to a lack of sterility assurance. This voluntary action, impacting nationwide distribution, poses significant supply chain and patient safety risks for healthcare providers relying on this critical antiseptic. Procurement and regulatory teams must assess immediate inventory and sourcing strategies.
FDA Class II Recall: CareFusion 213 LLC Initiates Voluntary Action on BD PurPrep
CareFusion 213 LLC, operating from its facility in El Paso, TX 79912-8000, has initiated a voluntary Class II recall for multiple lots of its BD PurPrep Povidone-iodine 8.3% w/w (0.83% available iodine) with Isopropyl Alcohol 72.5% w/w Sterile Solution. This critical antiseptic product, distributed nationwide in the USA, is packaged as 25x26mL applicators per carton, identified by NDC 54365-014-42 and 54365-014-41. The recall, designated D-0517-2026 and initiated on April 22, 2026, stems from a 'lack of assurance of sterility,' which indicates a potential for product contamination. For procurement directors, this means an immediate disruption to the supply of a widely used pre-operative skin preparation, necessitating urgent inventory checks and alternative sourcing strategies. Regulatory affairs heads must ensure compliance with recall procedures and prepare for potential increased scrutiny on similar products within their portfolios. The affected lots include 4258309, 4260329, 4256875 (expiring August 31, 2026); 4296453, 4317319, 4290654 (expiring September 30, 2026); and 4322449, 4323861, 4318679 (expiring October 31, 2026). The ongoing status of this recall underscores the need for continuous monitoring and proactive risk management.
Product Impact and Patient Safety: The Criticality of Sterile Antiseptics
The recalled BD PurPrep solution, comprising Povidone-iodine and Isopropyl Alcohol, is a human OTC drug primarily used topically as an antiseptic. Its application in healthcare settings, particularly for pre-surgical skin preparation, makes sterility an absolute requirement to prevent healthcare-associated infections. A 'lack of assurance of sterility' for such a product carries significant patient safety implications, potentially introducing pathogens into surgical sites or other vulnerable areas. For business development executives, this incident highlights the paramount importance of robust quality control in manufacturing sterile drug products. Any compromise on sterility not only triggers costly recalls but also erodes clinician trust and brand reputation, impacting future market penetration and sales. Supply chain VPs must recognize that a Class II recall, indicating a situation where the product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote, still demands immediate action to protect patients and maintain operational integrity. The widespread distribution of this product nationwide means the potential for contaminated units to reach numerous healthcare facilities, amplifying the risk.
Supply Chain Vulnerability: Nationwide Distribution and Sourcing Challenges
The nationwide distribution pattern of CareFusion 213 LLC's BD PurPrep means that healthcare systems across the United States are directly exposed to this supply disruption. Procurement directors must immediately identify all stock of the affected Povidone-iodine and Isopropyl Alcohol applicators within their networks, quarantine them, and initiate returns. The challenge lies in rapidly securing alternative sterile antiseptic solutions to maintain continuity of care, especially for high-volume surgical centers. This event underscores the fragility of single-source or limited-source procurement strategies for critical medical supplies. Supply chain VPs should leverage this incident to re-evaluate their supplier diversification strategies for essential topical antiseptics, considering both active pharmaceutical ingredient (API) and finished product manufacturers. The time and resources required to qualify new suppliers for sterile products can be substantial, emphasizing the need for pre-emptive risk assessments and contingency planning to avoid future shortages and ensure patient safety.
Broader Regulatory Landscape: A Trend of Sterility Assurance Deficiencies
This recall by CareFusion 213 LLC is not an isolated event but rather aligns with a concerning trend of sterility assurance deficiencies observed across the pharmaceutical and medical device industries. Recent parallel Class II recalls highlight this heightened regulatory focus. For instance, Essential Wellness Pharma faced a Class II recall for its Progesterone Injection in June 2026 due to similar sterility assurance failures. Just days prior, Spectra Medical Devices initiated a Class II recall for its Lidocaine HCl Injection, also citing sterility concerns. These incidents collectively signal an intensified FDA scrutiny on manufacturers' aseptic processing controls and quality management systems, particularly for injectable and topical sterile products. Regulatory affairs heads must interpret these events as a clear directive from the FDA: robust sterility validation, environmental monitoring, and comprehensive quality control are non-negotiable. Companies must proactively review their manufacturing processes and quality systems to identify and remediate potential vulnerabilities, thereby mitigating the risk of future recalls and avoiding more severe regulatory actions such as Warning Letters or Import Alerts.
Immediate Actions for Procurement and Regulatory Teams
For procurement directors, the immediate priority is to conduct a thorough inventory reconciliation of all BD PurPrep Povidone-iodine and Isopropyl Alcohol products. Identify and segregate all affected lot numbers (4258309, 4260329, 4256875, 4296453, 4317319, 4290654, 4322449, 4323861, 4318679) to prevent their use. Simultaneously, initiate contact with CareFusion 213 LLC for return instructions and explore immediate alternative sources for topical antiseptics. This may involve engaging with existing suppliers for similar products or expediting qualification processes for new vendors. Regulatory affairs heads must ensure that all internal stakeholders are informed of the recall and that appropriate documentation is maintained for audit purposes. This includes verifying that all affected product has been accounted for and that the firm's response aligns with FDA expectations. Business development executives should assess the competitive landscape for antiseptic solutions, as this recall creates an immediate market opportunity for compliant manufacturers to fill the supply gap, provided they can demonstrate robust sterility assurance.
Remediation and Future Outlook for CareFusion 213 LLC
As this is an ongoing voluntary recall, CareFusion 213 LLC is expected to be actively engaged in a comprehensive investigation into the root cause of the 'lack of assurance of sterility.' This will involve a detailed assessment of their manufacturing processes at the El Paso, TX facility, environmental controls, and quality management systems. The company will need to implement robust Corrective and Preventive Actions (CAPA) to address the identified deficiencies and prevent recurrence. For supply chain VPs, understanding the remediation timeline is crucial for assessing when, or if, supply from CareFusion 213 LLC might stabilize. Persistent or unresolved sterility issues could lead to further FDA enforcement actions, including an official Warning Letter or even an Import Alert if the company were to source components internationally with similar issues. The ability of CareFusion 213 LLC to demonstrate effective remediation will be critical for restoring market confidence and ensuring the long-term viability of its BD PurPrep product line. The industry will closely monitor the outcome of this recall as a benchmark for regulatory expectations in sterile product manufacturing.